文献速递帕金森病与运动障碍

成纤维细胞转录组学在全面性肌张力障碍队列分子诊断中的应用

Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort.
PubMed 文献 · Ann Neurol · 2026-02-02

该研究对167例肌张力障碍患者进行皮肤活检成纤维细胞RNA测序,分析表达与剪接异常。在无既往候选变异患者中获得6.9%(9/131)的诊断提升,所有新诊断均为常染色体隐性遗传的混合型肌张力障碍,且基于既往被忽视的剪接区或深部内含子变异。

要点

  • 成纤维细胞RNA-seq可检测>80%的肌张力障碍相关基因。
  • 对无既往候选变异患者,诊断提升为6.9%(9/131)。
  • 新诊断均基于剪接区或深部内含子变异。

核心结论

  • 在所选队列中,基于成纤维细胞的RNA-seq改善了变异解读,并在无既往候选变异的患者中提供了适度的诊断产出。

研究设计与样本

  • 研究纳入167例肌张力障碍患者,其中早发型占85.0%、非局灶型占92.2%、共存特征占76.0%。
  • 对皮肤活检样本进行RNA-seq,分析表达与剪接异常。
  • 36例(21.6%)有预先识别的变异,131例(78.4%)无既往优先诊断候选。

主要发现

  • >80%的肌张力障碍相关基因可通过成纤维细胞RNA-seq检测到。
  • 功能缺失变异中,66.7%(10/15)检测到疾病相关RNA低表达。
  • 其他预先识别变异类型中,28.6%(6/21)获得相关结果。
  • 无既往候选患者中诊断提升6.9%(9/131),均为常染色体隐性遗传的混合型肌张力障碍。
  • 新诊断基于既往被忽视的剪接区(3/9)和深部内含子(6/9)变异。

临床怎么用

  • 对于DNA测序未确诊的肌张力障碍患者,可考虑成纤维细胞RNA-seq辅助变异解读。
  • 尤其应关注剪接区和深部内含子变异的功能验证。

局限性

  • 诊断提升幅度有限(6.9%),且新诊断仅见于常染色体隐性遗传的混合型肌张力障碍患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Genomic sequencing leaves >50% of dystonia-affected individuals without a diagnosis. Where DNA-oriented approaches remain insufficient, integrating multiomics is essential to advance genome interpretation. Herein, we incorporated RNA sequencing (RNA-seq) data from 167 patients with dystonia across a range of ages and presentations. METHODS: We leveraged an RNA-seq analysis pipeline, focused on the identification of expression and splicing aberrations, on RNA-seq from skin biopsies. The recruited patients had early-onset dystonia in 85.0%, non-focal dystonia in 92.2%, and coexisting features in 76.0%. Thirty-six patient samples with pre-identified variants (36/167, 21.6%) and 131 samples with no previously prioritized diagnostic candidates from genomic sequencing (131/167, 78.4%) were evaluated. RESULTS: We found that >80% of dystonia-associated genes were detected by fibroblast RNA-seq. Expression and splicing aberration analyses produced a manageable number of significant RNA defects affecting dystonia-associated genes. The approach was especially successful in validating pathogenic effects of loss-of-function variants, with disease-relevant RNA-underexpression detected for 66.7% (10/15). Studying aberrant expression and splicing in the context of other pre-identified variant types yielded relevant results in 28.6% (6/21 samples). We obtained a 6.9% (9/131) diagnostic uplift for patients without prior candidates, all of whom exhibited combined dystonia with autosomal recessive inheritance. The new diagnoses from RNA-seq and genomic reanalysis were based on previously neglected splice-region (3/9) and deep(er) intronic (6/9) variants. For the observed events, integration of new machine-learning scores predicted corresponding aberrant gene expression in the brain. INTERPRETATION: Fibroblast-based RNA-seq in our selected cohort improved variant interpretation and offered a modest yield in patients without prior candidate variants. ANN NEUROL 2026;99:1363-1378.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Saparov A, Dzinovic I, Brunet T, et al. Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort. Ann Neurol. 2026. PMID: 41623120. doi:10.1002/ana.78171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。